Liquid Biopsy Market Overview
Liquid biopsy is a minimally invasive test that detects cellular or molecular biomarkers in body fluids like blood, urine, semen, or saliva, providing diagnostic, prognostic, or predictive disease information. Moreover, Liquid biopsy is utilized in clinical settings for early cancer detection, tumor staging and monitoring of localized cancer patients, predicting metastatic progression in advanced cancer patients, and monitoring treatment efficacy, although screening remains challenging.
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Rising Prevalence of Cancer
The liquid biopsy market is gaining demand due to the rising global cancer burden, which necessitates early detection and real-time monitoring for improved patient outcomes. Traditional methods are invasive and time-consuming, making liquid biopsy a non-invasive alternative. It allows for the detection of circulating tumor DNA, CTCs, and other biomarkers from blood samples, facilitating early diagnosis, treatment monitoring, and personalized therapy selection. For instance, the American Cancer Society (ACS) has revealed cancer statistics for 2025, estimating that more than 2 million new occurrences of cancer will be diagnosed in the United States this year, with over 600,000 people dying from cancer.
Researchers predict that in 2025, there will be 2,041,910 new cancer diagnoses in the United States, which equates to almost 5600 new cases every day. The figure comprises 1,053,250 cancer cases in males and 988,660 in women.
Standardization and Regulatory Challenges
One of the main things about retaining the global liquid biopsy market is the lack of standards and strict rules from regulators. Liquid biopsy technologies use complicated testing methods, and test results can be inconsistent when screening methods are changed. There aren't any generally agreed upon rules for validating tests, handling samples, and figuring out what the results mean, which makes it hard for broad adoption.
Also, regulatory bodies like the FDA and EMA need a lot of clinical support for liquid biopsy tests, which makes the approval process take longer. These problems make it take longer for new goods to reach the market and make it harder for smaller businesses to bring new liquid biopsy options to market.
Liquid Biopsy Market Segmentation Analysis
The global liquid biopsy market is segmented based on product type, circulating biomarker, application, technology, end user and region.
Rising Preference for Non-Invasive Cancer Diagnostics Drives the Kits & Reagents Segment
The Kits & Reagents segment represents a significant share of the global liquid biopsy market, supported by the recurring demand for consumables used in liquid biopsy workflows across research laboratories, diagnostic centers, and hospitals. The increasing adoption of minimally invasive cancer testing, coupled with growing utilization of next-generation sequencing (NGS), polymerase chain reaction (PCR), and companion diagnostic assays, continues to drive demand for high-quality reagent kits that enable accurate detection and monitoring of cancer-associated biomarkers. As precision oncology becomes more integrated into routine clinical practice, manufacturers are expanding their portfolios with advanced assay solutions designed to improve sensitivity, reproducibility, and workflow efficiency.
Reflecting this trend, in May 2025, Guardant Health introduced nearly a dozen new smart liquid biopsy applications for its Guardant360 Liquid test through the Guardant Infinity platform, expanding biomarker identification and tumor subtyping capabilities to support personalized cancer treatment decisions. The development highlights the industry's continued focus on enhancing liquid biopsy performance through advanced assay technologies and AI-enabled analytics.
Expanding Adoption of Circulating Tumor DNA (ctDNA) Analysis Accelerates the Circulating Biomarker Segment
Among circulating biomarkers, circulating tumor DNA (ctDNA) continues to witness strong adoption owing to its ability to provide real-time insights into tumor genetics, treatment response, minimal residual disease, and disease progression through a simple blood sample. Increasing demand for precision oncology, companion diagnostics, and longitudinal cancer monitoring is driving the integration of ctDNA-based testing across multiple cancer types. Technological improvements in sequencing sensitivity and bioinformatics are further enhancing the clinical utility of ctDNA in both advanced and early-stage cancer detection.
Supporting this momentum, in April 2025, Guardant Health announced a strategic collaboration with Pfizer to utilize its Guardant Infinity smart liquid biopsy platform in oncology research and clinical development, including the evaluation of ctDNA as a biomarker for monitoring treatment response across Pfizer's oncology portfolio. Such collaborations reinforce the growing importance of ctDNA-based liquid biopsy technologies in advancing precision medicine and accelerating the development of targeted cancer therapies.
Liquid Biopsy Regional Market Analysis
North America Liquid Biopsy Market
North America remains one of the leading markets for liquid biopsy due to its advanced healthcare infrastructure, widespread adoption of precision medicine, significant oncology research activities, and favorable reimbursement for selected molecular diagnostic tests.
The United States leads the regional market through extensive investments in cancer research, genomic medicine, companion diagnostics, and clinical implementation of liquid biopsy technologies. Strong collaborations between biotechnology companies, pharmaceutical firms, and academic institutions continue to accelerate innovation.
Major demand-generating applications include:
- Early Cancer Detection
- Companion Diagnostics
- Therapy Selection
- Treatment Monitoring
- Minimal Residual Disease (MRD) Detection
- Clinical Research and Drug Development
Asia-Pacific Liquid Biopsy Market
Asia-Pacific is expected to register the fastest growth during the forecast period due to rising cancer prevalence, expanding healthcare infrastructure, increasing awareness of early cancer diagnosis, and growing investments in molecular diagnostics.
China remains the largest market in the region, supported by expanding precision medicine initiatives, increasing genomic research, improving diagnostic capabilities, and government support for biotechnology innovation.
India is emerging as a major growth opportunity due to:
- Rising cancer burden
- Expansion of molecular diagnostic laboratories
- Growing adoption of precision oncology
- Increasing investments in biotechnology and genomics
- Improving access to advanced diagnostic technologies
Japan, South Korea, Australia, and Southeast Asian countries continue investing in genomic medicine, oncology diagnostics, and personalized healthcare to improve cancer management.
Europe Liquid Biopsy Market
Europe is witnessing steady market growth supported by strong oncology research, increasing adoption of precision medicine, favorable regulatory support for in vitro diagnostics, and expanding genomic testing programs.
Germany, the United Kingdom, France, Italy, and Spain remain key contributors due to well-established healthcare systems, extensive clinical research activities, and increasing use of molecular diagnostics in oncology.
The region is increasingly focusing on:
- Precision oncology programs
- Genomic profiling for personalized treatment
- Early cancer detection initiatives
- Companion diagnostic development
- Biomarker-driven clinical decision making
These initiatives continue to accelerate the adoption of liquid biopsy technologies across cancer diagnosis and treatment pathways.
Latin America Liquid Biopsy Market
Latin America is gradually strengthening its molecular diagnostics capabilities through expanding healthcare access, improving oncology care, and increasing adoption of advanced diagnostic technologies.
Countries such as Brazil, Mexico, Argentina, and Chile are witnessing growing implementation of liquid biopsy solutions across cancer diagnosis, treatment monitoring, and clinical research.
Increasing awareness of precision medicine, improving healthcare infrastructure, and expanding investments in cancer care are expected to support future market growth across the region.
Middle East & Africa Liquid Biopsy Market
The Middle East & Africa region is experiencing growing demand for liquid biopsy technologies due to improving cancer care infrastructure, increasing investments in precision medicine, and expanding access to advanced molecular diagnostics.
Saudi Arabia and the United Arab Emirates are leading regional investments in genomic medicine, oncology centers, and advanced diagnostic capabilities as part of broader healthcare modernization initiatives.
Liquid Biopsy Market Major Global Players
The major global players in the liquid biopsy market include Exosome Sciences Inc., Illumina, Inc., Guardant Health, Thermo Fisher Scientific Inc., NeoGenomics Laboratories, Qiagen, BioChain Institute Inc., Sysmex Europe SE, Eurofins Genomics, and Goffin Molecular Technologies among others.
Key Developments of the Liquid Biopsy Market
June 2026: Guardant Health announced FDA approval of Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS®, further expanding the clinical utility of its liquid biopsy platform in precision oncology. The approval strengthens blood-based genomic profiling for therapy selection and reinforces the growing role of liquid biopsy in targeted cancer treatment.
- May 2026: Guardant Health received FDA approval for the new Guardant360 Liquid CDx, featuring its largest FDA-approved liquid biopsy panel with a significantly expanded genomic footprint. The next-generation assay enhances biomarker detection capabilities and supports broader precision medicine applications across multiple solid tumors.
- February 2026: Guardant Health launched its Community Colorectal Cancer Screening Grant Program to accelerate adoption of blood-based colorectal cancer screening and improve access through community partnerships. The initiative reflects continued investment in advancing early cancer detection and expanding the real-world implementation of liquid biopsy technologies.
Key Takeaways
- The increasing adoption of precision medicine and non-invasive cancer diagnostics is emerging as a key industry trend, with healthcare providers and diagnostic developers focusing on liquid biopsy technologies that enable earlier disease detection, real-time treatment monitoring, and personalized therapeutic decision-making.
- North America maintains a leading position in the global market, driven by the presence of advanced healthcare infrastructure, strong oncology research capabilities, favorable reimbursement for molecular diagnostics, and widespread adoption of next-generation sequencing and companion diagnostic technologies.
- Asia-Pacific is projected to record the fastest growth during the forecast period, supported by rising cancer prevalence, expanding access to advanced diagnostic services, increasing investments in genomic medicine, and growing government initiatives to strengthen precision oncology across emerging healthcare markets.
- The rising global burden of cancer and the increasing demand for minimally invasive diagnostic procedures are becoming major factors accelerating the adoption of liquid biopsy solutions for early detection, recurrence monitoring, and treatment response assessment.
- Growing technological advancements in circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, and multi-analyte biomarker platforms are improving diagnostic accuracy, sensitivity, and clinical utility, further strengthening market growth.
- Industry participants are increasingly prioritizing investments based on clinical validation, regulatory approvals, biomarker innovation, genomic sequencing capabilities, and strategic collaborations with pharmaceutical companies to support precision medicine and companion diagnostics.
- Expanding applications of liquid biopsy in cancer screening, therapy selection, minimal residual disease (MRD) monitoring, clinical trials, and longitudinal disease surveillance are creating significant growth opportunities for diagnostic companies, biotechnology firms, and precision medicine stakeholders worldwide.
Liquid Biopsy Market Scope
| Metrics | Details | |
| CAGR | 10.7% | |
| Market Size Available for Years | 2023-2033 | |
| Estimation Forecast Period | 2026-2033 | |
| Revenue Units | Value (US$ Bn) | |
| Volume (Units) | ||
| Segments Covered | Product Type | Kits & Reagents, Instruments, Services |
| Circulating Biomarker | Circulating Tumor Cells, Circulating Tumor DNA (ctDNA), Cell-free DNA (cfDNA), Extracellular Vesicles | |
| Application | Cancer Applications, Non-Cancer Applications | |
| Technology | Multi-gene-parallel Analysis (NGS), Single Gene Analysis (PCR Microarrays) | |
| End User | Hospitals and Physician Laboratories, Research Centers, Others | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa | |
Why Purchase the Report?
- Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
Target Audience
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Product Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
The global liquid biopsy market report delivers a detailed analysis with 61 key tables, more than 59 visually impactful figures, and 220 pages of expert insights, providing a complete view of the market landscape.
